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Enantiomeric separation and quantitative determination of propranolol
enantiomers in pharmaceutical preparations by chiral liquid
chromatography
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This paper describes validated direct liquid chromatographic chiral
methods for enantiomeric separation and quantitative
determination of clinically significant β-blocking agent,
propranolol. A liquid chromatographic method was validated and
applied for enantiomeric determination of propranolol enantiomers
in pharmaceutical formulations. Separation were obtained in polar
organic mode on a α-Burke 2® chiral stationary phase (250 x 4.6
mm, 5µm) with mobile phase composed of dichloro-
methane:methanol (90:10 v/v), along with 12 mM of ammonium
acetate, at a flow rate of 0.9 mL/min. Detection was made by
ultraviolet absorption at 280 nm. In all cases the run time was less
than 10 min. The correlation coefficient for linear regression curves
of R-propranolol and S-propranolol were 0.9995 and 0.9998
respectively. The intra-day precision, expressed as RSD was less
than 2%. The accuracy determined by average recovery of R-
propranolol and S-propranolol from sample matrices were 97.3%
and 100.1% in commercial sample and 99.5% and 100.4% in
simulated samples, respectively. Excellent levels of limit of detection
(mean value = 1.34 ng) and limit of quantitation (mean value =
4.47 ng), along with rapid elution time of both enantiomers, makes
the method useful for routine enantiomeric quality control
applications.
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Recent important advances in enantiomerically pure
pharmaceuticals and the need for stereoselective quality
control require constant development of validated efficient
analytical methods. Direct enantiomeric separation and
determination with liquid chromatography using chiral
stationary phases (HPLC-CSP) have already been
accepted as standard analytical technique (Santoro, Cho,
Kedor-Hackmann, 2001; Schmid et al., 2001; Singh,
Kedor-Hackmann, Santoro, 2001; Phem-Huy et al., 1995;
Egginger et al., 1993; Aboul-Enein, Al-Duraibi, 1999;
Mislanova et al., 2000; Aboul-Enein, Bakr, 1998; Matchett,
Branch, Jefferies, 1996; Aboul-Enein, Abou-Basha, Bakr,
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1996; Ekelund et al., 1995; Petersen et al., 1997). Surely
constant development of new efficient HPLC-CSP
methods and thorough validation studies contributes to
ensure accurate and reproducible determination of
enantiomers in pharmaceuticals.
Propranolol (DL-1-(isopropylamino)-3-(1-
naphthyloxy)-2-propanol) is a potent β-adrenergic
antagonist drug, predominantly used in the treatment of
angina pectoris, systemic and renal hypertension, cardiac
arrhythmias and several other cardiovascular disorders
(Barrett, Cullum, 1968; Moffat et al., 1986). Its molecular
structure contains an aromatic naphthyloxy group attached
to a side alkyl chain possessing a secondary hydroxyl and
amine functional group (Figure 1). It possesses two
enantiomers due to the presence of a chiral carbon in the
alkyl side chain, adjacent to a hydroxyl group. The well
acknowledged differential pharmacodynamic and
pharmacokinetic profiles of R- and S-enantiomers
rationalize their separation and determination in
pharmaceuticals as well as in other relevant matrices.
Several indirect (Barrett, Cullum, 1968; Silber,
Riegelman, 1980; Walle et al., 1984; Yang et al., 1997) as
well as direct liquid chromatographic methods (Santoro,
Cho, Kedor-Hackmann, 2001; Schmid et al., 2001; Phem-
Huy et al., 1995; Egginger et al., 1993; Aboul-Enein, Al-
Duraibi, 1999; Mislanova et al., 2000; Aboul-Enein, Bakr,
1998; Matchett, Branch, Jefferies, 1996; Ekelund et al.,
1995; Petersen et al., 1997; Chiral Application Guide,
2000) have been reported for their analysis. Most of these
methods are shown to be useful for enantiomeric
determination in biological samples (Phem-Huy et al.,
1995; Egginger et al., 1993; Mislanova et al., 2000; Silber,
Riegelman, 1980; Yang et al., 1997; Stoschitzky et al.,
1995) but seldom in quality control or stability studies
(Santoro, Cho, Kedor-Hackmann, 2001; Singh, Kedor-
Hackmann, Santoro, 2001; Petersen et al., 1997). In a
previous work, enantiomeric separations and a quantitative
determinations of atenolol and metoprolol (Singh, Kedor-
Hackmann, Santoro, 2001) and propranolol (Santoro, Cho,
Kedor-Hackmann, 2001) in pharmaceutical formulations,
using cellulose based CSP (Chiralcel OD®) were presented.
In the present paper an improved, specific, accurate and
reproducible method for rapid routine stereospecific and
quantitative analysis of propranolol (prop) enantiomers in a




The description of the samples studied is presented
in Table I. The simulated sample (sample B) was prepared
by mixing equivalent amount of racemic prop with
excipients (Table I).
Reagents and solutions
Racemic prop. HCl (99%), R-prop. HCl (98%) and
S-prop. HCl (98%) were purchased from Aldrich
(Milwaukee, WI, USA). All the solvents were of HPLC
grade except ammonium acetate (analytical grade).
Dichloromethane, methanol and ammonium acetate were
obtained from Merck® (Darmstadt, Germany).
TABLE I - Representative commercial and simulated tablet samples selected for analysis
Sample Drug Tablet composition
    A Racemic prop (40 mg)/tablet Commercial sample containing prop, starch, microcrystalline cellulose,
lactose (monohydrate), gelatin, magnesium stearate (Mean wt. = 0.157 g)
    B Racemic prop (40 mg)/tablet Simulated sample prepared in laboratory with same composition as sample
A (Mean wt. = 0.160 g)
Placebo None Starch, microcrystalline cellulose, lactose (monohydrate), gelatin,
magnesium stearate (Mean wt. = 0.160 g)
FIGURE 1 - Structure of (R) and (S)-propranolol.
Enantiomeric separation and quantitative determination of propranolol 303
Equipments
A liquid chromatographic system consisted of a
solvent delivery system, an auto injector fitted with 50 µL
loop, an online degaseification system, a column thermostat
oven; an UV/VIS photodiode array detector (Shimadzu
Corporation, Japan) and a chiral stationary phase (S, S) α-
Burke 2® (250 x 4,6 mm i.d.) [dimethyl N-3,5-dinitro-
benzoyl-α-amino-2,2-dimethyl-4-pentenylphosphonate]
covalently bound to 5 µm mercaptopropyl silica, 100 A°




Analytical conditions for prop were standardized
through high performance liquid chromatography system
using α-Burke 2® as chiral stationary phase. The samples
were chromatographed at room temperature (24 °C ± 2),
with an injection volume of 20 µL, a flow rate of 0.9 mL/min,
UV detection was made at 280 nm. The mobile phase was
constituted by a mixture of dichloromethane:methanol (90:10
v/v), along with 12 mM ammonium acetate. The mobile
phase was prepared fresh each day and vacuum filtered
through hydrophobic membrane, 0.22 µm, Millipore® GVHP,
and degassed for 20 minutes. The conditioning of the CSP
was done by washing the system for 90 minutes with the
mobile phase prior to injections.
Calibration curve
The calibration curve was constructed by analyzing in
triplicate, nine different calibration standards ranging from
1.0 to 16.0 µg/mL of R- or S-prop, separately. The stock
solution of R-prop and S-prop were prepared separately by
weighing exactly 20.0 mg of standard, free base, in a 50 mL
volumetric flask. Approximately 45 mL of methanol was
added, followed by ultrasonication for 10 min. The volume
was completed with the same solvent. An aliquot of 5.0 mL
was transferred to a 100 mL volumetric flask and volume
made up with mobile phase to obtain solutions containing
20.0 µg/mL of R-prop or S-prop. Appropriate dilutions were
made with mobile phase to obtain nine concentration levels
between 1.0–16.0 µg/mL of each enantiomer. Calibration
curve was constructed by plotting mean peak-area of the
individual enantiomer versus enantiomer concentration
injected.
Preparation of standard solution for intra-day
repeatability
Standard solution containing 400.0 µg/mL of R- or S-
prop was prepared separately, as explained in calibration
curve section. A 5.0 mL aliquot of R-prop and equal volu-
me of S-prop solution were transferred to a 100 mL
volumetric flask and volume was made up with mobile
phase. The final solution contains 40.0 µg of racemic
prop/mL of solution.
Preparation of sample solutions for intra-day
repeatability
Amounts of sample A or B, in triturated form,
equivalent to 40.0 mg of prop free base was accurately
weighed and transferred to a 100 mL volumetric flask.
Approximately 95 mL of methanol was added to it and
ultrasonicated for 10 min. The volume was completed with
the same solvent. After filtration through Whatman no. 1
paper filter, 5.0 mL of filtrate was transferred to a 50 mL
volumetric flask and the volume was made up with the
mobile phase. The final solution contains 40.0 µg of
racemic prop/mL of solution.
Three final dilutions containing 3.2, 16.0 and
32.0 µg/mL of racemic prop were obtained by appropriate
dilution of above standard and sample solutions with mo-
bile phase. Six replicates of each sample solution (sample
A and B) and triplicate injection of standard solutions, were
injected (20 µL) into the HPLC system. All the solutions,
before injection, were filtered through HV Millex,
Durapore® membrane, 0.45 µm, 13 mm.
Sample preparation for recovery test
Standard solution and sample solutions (A and B)
were prepared separately as described above to obtain
40.0 µg/mL of racemic prop. The method accuracy was
accessed by determining the agreement between the
difference in the measured analyte concentrations of the
fortified and unfortified samples and the known amount of
analyte added to the fortified sample. Single enantiomer
solutions with known concentrations were used to fortify
racemic sample solution. Triplicate determinations were
performed at three concentration levels. Further details are
presented in Table V (Jenke, 1996; ICH, 2001).
RESULTS AND DISCUSSION
The routine analysis of asymmetric pharmaceuticals
by HPLC-CSP or by indirect method is vastly followed in
pharmaceutical industries for quality control of
enantiomerically pure and racemic mixtures. Each day new
pharmaceuticals are commercially made available and
necessitates constant development of rapid, efficient and
sensitive methods for their quantitative determination,
especially when one of the enantiomers is present as
impurity in a pharmaceutical dosage form.
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Enantiomeric separation
Prop is a basic molecule with pKa 9.5 (Moffat et al.,
1986). The manufacturers of α-Burke 2® CSP (Chiral
Application Guide, 2000) recommend utilization of
ammonium acetate at low concentration (10–40 mM) for
peak elution and improvement of peak shape. Systematic
experiments were conducted to study the effect of
ammonium acetate concentration and operating temperature
on enantiomeric resolution, retention time and peak
asymmetry. Most efficient separation was obtained at room
temperature utilizing mobile phase constituted of
dichloromethane:methanol (90:10 v/v) with 12 mM of
ammonium acetate at a flow rate of 0.9 mL/min. Detection
was made at 280 nm (Figure 2). All conditions were selected
for validation of method keeping in view practical application
of proposed method for efficient routine analysis of prop
enantiomers in pharmaceutical formulations.
System suitability test
System suitability tests are an integral part of all liquid
chromatographic methods. The test was performed by
repeated analysis of sample solution (n=6) and relative
FIGURE 2 - Enantiomeric separation of propranolol in pharmaceutical formulation, (a) R-prop standard (16.0 µg/mL);
(b) S-prop standard (16.0 µg/mL); (c) (R/S)-prop sample (32.0 µg/mL). Conditions: Column: CSP α-Burke 2®, mobile
phase: dichloromethane:methanol (90:10 v/v), along with 12 mM of ammonium acetate, flow rate: 0.9 mL/min, UV
detection: 280 nm, oven temperature 24 °C ± 1, injection volume: 20 µL.
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standard deviation amid elution parameter studied. There
was insignificant deviation in the values of relative retention
(k1 and k2) selectivity (α), resolution (Rs) and number of
theoretical plates (N) (Table II).
Selectivity
The formulation excipients did not interfere in the
analysis of enantiomers. The placebo sample injected under
similar analytical conditions demonstrated selectivity of the
proposed method. The elution order of R- and S-prop was
determined by injecting them, separately, into the system.
Linearity
The calibration curves for R- and S-prop were
constructed at nine concentration levels in the range from
1.0 to 16.0 µg/mL, and triplicate determination was made
at each level (n=3). Two calibration curves, one for each
enantiomer, were constructed by plotting mean response
area against corresponding concentration injected, using
the least squares method. The correlation coefficient for
R-prop (r = 0.9995) and for S-prop (r = 0.9998) along with
other relevant data, indicates good linearity (Table III).
Low concentration ranges were intentionally selected to
make the proposed method especially useful for the
determination of R- or S-prop impurities in the presence of
its antipode.
Limit of detection and limit of quantitation
The limit of detection (LOD) and limit of quantitation
(LOQ) with acceptable precision (RSD < 2 %) (Jenke,
1996) were determined based on the standard deviation
(SD) of the responses and the slope of the calibration
curve (S), via equation LOD = 3 x (SD/S) and LOQ = 10
x (SD/S). The calculated theoretical values were cross
checked by actual analysis (in triplicate) of refereed
concentrations and relative standard deviation of the
responses determined. The limit of detection values for R-
prop and S-prop were 1.31 ng and 1.37 ng and
corresponding values for limit of quantitation were 4.37 ng
and 4.58 ng, respectively (Table III). Unlike previously
reported liquid chromatographic methods, the proposed
method presents excellent sensitivity in the determination
of R- and S-prop.
Precision
Method precision was determined by measuring
intra-day repeatability of responses for R-prop and S-prop
in commercial and simulated samples. The analysis were
carried out at three concentration levels, i.e. 3.2, 16.0 and
32.0 µg/mL of racemic sample A or sample B. Variations
were expressed in terms of relative standard deviation
values calculated from six replicate determination at each
concentration level of R- and S-prop. The low level of RSD
with excellent confidence limits indicates good precision of
the proposed method (Table IV).
Accuracy
Method accuracy was determined at three
concentration levels i.e. 8.0, 10.0 and 12.0 µg/mL, with
triplicate determination at each concentration level. The
accuracy of the method was expressed as average
recovery of the analyte from the sample matrix (Sample A
and sample B) (Jenke, 1996; ICH, 2001). The three


































1.62 2.1 1.3 3.0 6724 (R-prop) 5184(S-prop)
TABLE III - Linearity of the calibration curve for R- and S-
propranolol enantiomers
Parameter R-propranolol S-propranolol
Concentration range 1.0 – 16.0 * 1.0 – 16.0 *
   (µg/mL)
Calibration points 9 9
Linearity
   Intercept 2038.2 119.39
   Slope 21122 21157
   Correlation coefficient 0.9995 0.9998
Limit of detection * 1.31 ng 1.37 ng
Limit of quantitation * 4.37 ng 4.58 ng
* average of three determinations
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concentrations were selected in such a way, so that, they
fall within 80.0–120.0% of the mean value and at the
same time covering the same range as that for linearity
(AOAC, 1990). The recoveries of R- as well as S-prop
from sample matrices were near 100 percent with
acceptable deviations (Table V).
CONCLUSION
The proposed method for enantiomeric separation
and quantitative determination of prop enantiomers in
tablets and bulk drugs is efficient and sensitive. The
excipients of the commercial sample analyzed did not in-
terfere in the analysis, which proved the enantio-
specificity of the method. The ease of sample preparation
permits fast and efficient application of the proposed
method in quantitation of prop with precision and
accuracy. The shorter analysis time permits its application
in the routine quality control of prop enantiomers in
commercial samples.
TABLE IV - Statistical data showing precision of the proposed method, at three concentration levels (n=6), in the
determination of propranolol enantiomers in samples A and B
Sample Enantiomer Conc. of racemic Peak area Standard deviation Relative standard
sample (µg/ml) (SD) deviation (RSD)
A R-prop 2.0 34030 465 1.50
4.0 165263 597 0.39
6.0 336112 853 0.28
S-prop 2.0 34858 421 1.32
4.0 173015 2229 1.41
6.0 350125 3739 1.71
B R-prop 2.0 34450 380 1.21
4.0 168225 869 0.58
6.0 338952 1701 0.55
S-prop 2.0 35495 463 1.43
4.0 175982 1713 1.07
6.0 356902 3808 1.17
TABLE V - Statistical data showing accuracy of the proposed method, at three concentration levels (n=3), in the
determination of propranolol enantiomers in samples A and B
Sample Enantiomer Concentration added Concentration Percentage
(µg/mL) found ± RSD recovered (%)
A R-prop 2.0 1.93 ± 0.57 96.50
4.0 3.89 ± 0.52 97.30
6.0 5.90 ± 0.50 98.30
S-prop 2.0 1.95 ± 1.09 97.50
4.0 4.01 ± 0.57 100.20
6.0 6.16 ± 0.64 102.70
B R-prop 2.0 2.00 ± 0.26 100.00
4.0 3.98 ± 0.59 99.50
6.0 5.94 ± 0.48 99.00
S-prop 2.0 2.02 ± 1.35 101.00
4.0 4.05 ± 1.27 101.20
6.0 5.94 ± 1.93 99.00
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RESUMO
Separação e determinação quantitativa dos
enantiômeros do propranolol em preparações
farmacêuticas por cromatografia quiral
Neste trabalho é descrito um método validado empre-
gando a cromatografia líquida de alta eficiência com
fase estacionária quiral para a separação e determi-
nação quantitativa dos enantiômeros do propranolol
em formulações farmacêuticas. A separação foi obti-
da em meio orgânico polar empregando a coluna α-
Burke 2® como fase estacionária quiral (250 x 4,6 mm,
5μm) e fase móvel constituída por diclorometano:
metanol (90:10 v/v) juntamente com 12 mM de acetato
de amônio e vazão de 0,9 mL/min. A detecção foi efe-
tuada por absorção no ultravioleta a 280 nm. Em to-
dos casos o tempo de corrida foi menor do que 10 min.
O coeficiente de correlação obtido pelo método de
regressão linear foi de 0,9995 para o R-prop e de
0,9998 para o S-prop. A precisão intra-dia, expressa
como desvio padrão relativo, foi menor do que 2%. A
exatidão, determinada pela recuperação média de R-
e S-prop nas amostras foi de 97,3% e 100,1% para a
amostra comercial e de 99,5% e 100,4% para a amos-
tra simulada, respectivamente. Excelentes níveis para
os limites de detecção (1,34 ng) e de quantificação
(4,47 ng), além do tempo rápido de eluição dos
enantiômeros do propranolol, confirmam a
aplicabilidade do método no controle de qualidade de
preparações farmacêuticas contendo este fármaco.
UNITERMOS: Separação enantiomérica.
Cromatografia líquida. Validação do método.
Propranolol. Comprimidos.
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